CORRECTION

Correction to: Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects

Joris Vandenbossche · Wolfgang Jessner · Maarten van den Boer ·
Jeike Biewenga · Jan Martin Berke · Willem Talloen · Loeckie De Zwart ·
Jan Snoeys · Koen Vandyck · John Fry · Jeysen Yogaratnam

Published online: March 4, 2020
© Springer Healthcare Ltd., part of Springer Nature 2020

Correction to: Adv Ther (2019) 36:2450–2462
<https://doi.org/10.1007/s12325-019-01017-1>

In the original article ninth and tenth authors were incorrectly omitted from the author group. The correct author group is Joris Vandenbossche, Wolfgang Jessner, Maarten van den Boer, Jeike Biewenga, Jan Martin Berke, Willem Talloen, Loeckie De Zwart, Jan Snoeys, Koen Vandyck, John Fry, Jeysen Yogaratnam.

Their affiliations are as follows:

Koen Vandyck: Janssen Pharmaceutica NV, Beerse, Belgium

John Fry: Janssen Biopharma, Inc., South San Francisco, CA, USA

The correct disclosures are given below:

Disclosures Joris Vandenbossche is a Janssen employee and a Johnson & Johnson stockholder. Wolfgang Jessner was part of Janssen Pharmaceutica at the time of this study and is

The original article can be found online at <https://doi.org/10.1007/s12325-019-01017-1>.

J. Vandenbossche (✉) · W. Jessner · J. Biewenga ·
J. M. Berke · W. Talloen · L. De Zwart · J. Snoeys ·
K. Vandyck
Janssen Pharmaceutica NV, Beerse, Belgium
e-mail: jvdbossc@its.jnj.com

M. van den Boer
Janssen Pharmaceutica NV, Merksem, Belgium

J. Fry · J. Yogaratnam
Janssen Biopharma, Inc., South San Francisco, CA,
USA

now employed by Roche Pharma Research & Early Development, Basel, Switzerland and a Johnson & Johnson and Roche stockholder. Maarten van den Boer was a Janssen employee at the time of the study and is a Johnson & Johnson stockholder. Maarten van den Boer is currently a freelancer. Jeike Biewenga is a Janssen employee. Jan Martin Berke is a Janssen employee and a Johnson & Johnson stockholder. Willem Talloen is a Janssen employee and a Johnson & Johnson stockholder. Loeckie De Zwart is a Janssen employee and a Johnson & Johnson stockholder. Jan Snoeys is a Janssen employee and a Johnson & Johnson stockholder. Koen Vandyck was a Janssen employee at the time of the study. Koen Vandyck's current affiliation is Aligos Therapeutics, Leuven, Belgium. John Fry was a Janssen employee at the time of the study. John Fry's current affiliation is Aligos Therapeutics, South San Francisco, CA, USA. Jeysen Z. Yogaratnam was a Janssen employee at the time of the study and has a patent application pending. Jeysen Z. Yogaratnam's current affiliation is Aligos Therapeutics, South San Francisco, CA, USA.